BioSpace News Archive

Tonix Pharmaceuticals Holding Corp. today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will participate virtually in the BIO CEO & Investor Conference, which is being held February 6-9, 2023.

Celldex Therapeutics, Inc. announced today that data from the Company’s Phase 1b multi-dose study of barzolvolimab in chronic spontaneous urticaria will be presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023 being held February 24-27 in San Antonio, Texas.

Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today reported recent company updates and financial results for its fiscal third quarter ended December 31, 2022.

Azenta, Inc. (Nasdaq: AZTA) today announced that it has acquired Ziath, Ltd. and its subsidiaries (“Ziath”). Based in Cambridge, UK, Ziath is a leading provider of 2D barcode readers for life sciences applications.

Bruker today announced successful customer installations of two novel, compact 1.0 GHz NMR spectrometers for advanced structural and molecular biology applications well ahead of original schedules in late 2022.

Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at the Guggenheim Healthcare Talks 2023 Oncology Conference on Thursday, February 9, 2023.

Neurent Medical today announced its NEUROMARK ® Rhinitis Neurolysis Therapy (RNT) is now commercially available in limited U.S. markets.

Monte Rosa Therapeutics, Inc. today announced the company is scheduled to participate in fireside chats and industry panels, as well as present at the following upcoming investor events.

Invivyd, Inc. today announced that Laura Walker, Ph.D., the company’s chief scientific officer and co-founder, decided to leave the company to pursue other opportunities.

Gracell Biotechnologies Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared Gracell’s Investigational New Drug (IND) application and the Company can proceed to initiate a Phase 1b/2 clinical trial in the U.S. of GC012F, an autologous CAR-T therapeutic candidate, for the treatment of relapsed/refractory multiple myeloma (RRMM).